Sun Pharma subsidiary to acquire 12.5 per cent stake in Australia-based WRS Bioproducts (See 'Corp Brief') TVS Motor to provide free COVID-19 vaccines to all 35,000 employees (See 'Corp Brief') Mahindra Finance appoints Amit Raje as COO of digital business (See 'Corp Brief') Entry of Wildlife Crime Control Bureau in notification dated 27th June, 2006 (See 'Dashboard') Arbitration and Conciliation Act - Delhi High Court has no jurisdiction to appoint arbitrator as matter involve international commercial arbitration - SC (See 'Legal Desk') CCI holds National Conference on Economics of Competition Law (See 'Corp Brief') Guidelines for votes cast by Mutual Funds (See 'Dashboard') ArcelorMittal Nippon Steel India to set up Rs 50,000Cr steel plant in Odisha (See 'Corp Brief') BSE inks JV with Frontier Agriculture Platforms to drive innovation in agriculture (See 'Corp Brief') Circular on Mutual Funds (See 'Dashboard') Wipro acquires Capco in USD 1.45 billion Tech Mahindra inks agreement with ThoughtSpot to offer real-time analytics for enterprises globally Arbitration - Only award that is not deemed proper, intelligible and adequate, warrants interference of High Court: HC (See 'Legal Desk') Web Werks enters into strategic relationship with Iron Mountain with investment of USD 150mn Arbitration - Consenting and finalizing, date of separation is one of most crucial and preliminary steps to be taken in a partition deed: HC (See 'Legal Desk') Companies Act - NCLT has overreached its scope of Judicial Intervention in determining Scheme of Amalgamation by failing to point out material irregularities according to its judicial scrutiny: NCLAT (See 'Legal Desk') PFUTP Regulations, 2003 - Charge of raising price artificially must be established to prove charge of collusion between buyer and seller: SAT (See 'Legal Desk') Power to Remand cases curtailed in GST (See 'taxindiaonline.com') Honeywell Automation India names Ganesh Natarajan as chairman (See 'Corp Brief') Wipro to acquire UK-based consultancy Capco for USD 1.45Bn (See 'Corp Brief') Infosys to double Canadian workforce to 4,000 by 2023 (See 'Corp Brief') IEX electricity market sees 50 per cent growth in February (See 'Corp Brief') Ashoka Buildcon to buy 49 per cent stake in Ashoka Highways (Bhandara) from IIF (See 'Corp Brief') Spain's GMV Sistemas debarred by World Bank Group for corrupt practices (See 'Corp Brief') Capgemini collaborates with UN to empower Indian youth (See 'Corp Brief') MDL pays interim dividend of Rs 92.56Cr for FY21 (See 'Corp Brief')

Glenmark's Swiss arm gets nod to market Ryaltris nasal spray in Russia

Published: Feb 22, 2021

By TIOLCORPLAWS News Service

NEW DELHI, FEB 22, 2021: GLENMARK Pharmaceuticals on Monday said its Swiss subsidiary, Glenmark Specialty, has received marketing approval from Russian health regulators for its fixed-dose combination nasal spray, Ryaltris.

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, like stuffy and runny nose, nasal itching, sneezing, as well as irritated eyes, in adults and children over 12 years of age.

"Glenmark has built strong capabilities in the area of respiratory medicine and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," said Csaba Kantor, Senior Vice President - Russia and CIS region, Glenmark.

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent.

"Glenmark has a strong established presence in Russia for over 30 years, which will enable us to lead the commercialization of this product in the country. We look forward to being able to make this innovative product available to patients in Russia as soon as possible," Mr Kantor added.

The company estimated that Ryaltris will be available to patients in Russia by the first quarter of 2021-22.

TIOL CORP SEARCH

TIOL GROUP WEBSITES